The video refers to the Sangamo trial - not Calimmune. HBV...

The video refers to the Sangamo trial - not Calimmune.

HBV concerns me because I am not even sure that we have firmed up on the target(s). The safety and biodistribution data of the AAV8 vector we can borrow from the TT-034 trial but that still leaves safety testing for silencing the target. I think HBV is still a couple of years away from the clinic let alone the market. Even the pipeline chart shows the HBV program in the Discovery phase. This is why news of Tribetarna would be good because that is the real back-up strategy for proving ddRNAi.